Your fact-checks will appear here
The use of vaccines to prevent COVID-19
High‑dose ivermectin studies in humans and pharmacovigilance analyses document a spectrum of neurologic events—from common, mild symptoms such as dizziness and somnolence observed in trials to rare bu...
Peer‑reviewed population studies and systematic reviews consistently show myocarditis after mRNA COVID‑19 vaccination is rare, concentrated among adolescent and young adult males—most commonly within ...
Since 2020 major health agencies have consistently said that ivermectin is not authorized or approved to prevent or treat COVID‑19 and have discouraged its routine use outside clinical trials, while r...
A single dose of the Novavax 2024–2025 formulation (JN.1-based) is authorized for use in vaccine‑naïve individuals ≥12 years in the United States, and regulatory documents describe a single‑dose regim...
are not “bad” in any blanket sense: the scientific consensus is that vaccines have saved millions of lives, remain effective tools against infectious disease, and are subject to ongoing ; at the same ...